Inhibition of spleen tyrosine kinase as treatment of postoperative ileus

Gut

Volumn 62, Issue 11, 2013, Pages 1581-1590

  Van Bree, Sjoerd H W ^a   Gomez Pinilla, Pedro Julian ^b   Van De Bovenkamp, Fleur Suzanne ^a   Giovangiulio, Martina Di ^b   Farro, Giovanna ^b   Nemethova, Andrea ^b   Cailotto, Cathy ^a   De Jonge, Wouter J ^a   Lee, Kevin ^c   Ramirez Molina, Cesar ^c   Lugo, Dave ^c   Skynner, Michael J ^c   Boeckxstaens, Guy E E ^a,b   Matteoli, Gianluca ^b,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; COMPOUND 143; DOXANTRAZOLE; GSK 143; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; SUBSTANCE P; TRINITROPHENYL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; ENZYME RELEASE; GASTROINTESTINAL TRANSIT; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUSCLE; MACROPHAGE; MACROPHAGE ACTIVATION; MAST CELL DEGRANULATION; MOUSE; MYOSITIS; NONHUMAN; PERITONEUM MAST CELL; POSTOPERATIVE ILEUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ABDOMINAL SURGERY; INFLAMMATION; INTESTINAL MOTILITY; MACROPHAGES; MAST CELLS;

ANILINE COMPOUNDS; ANIMALS; CELL DEGRANULATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRANSIT; ILEUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGE ACTIVATION; MAST CELLS; MICE; MICE, INBRED C57BL; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SUBSTANCE P; THIOXANTHENES; XANTHONES;

EID: 84885661720     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302615     Document Type: Article

References (50)

1. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 2009;58:1300-11.
2. Kalff JC, Carlos TM, Schraut WH, et al. Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus. Gastroenterology 1999;117:378-87. (Pubitemid 29352946)
3. Moore BA, Turler A, Pezzone MA, et al. Tyrphostin AG 126 inhibits development of postoperative ileus induced by surgical manipulation of murine colon. Am J Physiol Gastrointest Liver Physiol 2004;286:G214-24. (Pubitemid 38134032)
4. The FO, de Jonge WJ, Bennink RJ, et al. The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br J Pharmacol 2005;146:252-8. (Pubitemid 43079965)
5. de Jonge WJ, van den Wijngaard RM, The FO, et al. Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. Gastroenterology 2003;125:1137-47. (Pubitemid 37193460)
6. The FO, Buist MR, Lei A, et al. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol 2009;104: 2257-66.
7. Abu-Dalu R, Zhang JM, Hanani M. The actions of ketotifen on intestinal smooth muscles. Eur J Pharmacol 1996;309:189-93. (Pubitemid 26268496)
8. Dyson AJ, Mackay AD. Ketotifen in adult asthma. Br Med J 1980;280:360-1. (Pubitemid 10217259)
9. Schwarzer G, Bassler D, Mitra A, et al. Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database Syst Rev 2004;(1):CD001384.
10. Rivera J, Olivera A. A current understanding of Fc epsilon RI-dependent mast cell activation. Curr Allergy Asthma Rep 2008;8:14-20. (Pubitemid 351459688)
11. Rossi AB, Herlaar E, Braselmann S, et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol 2006;118:749-55. (Pubitemid 44301399)
12. Wehner S, Behrendt FF, Lyutenski BN, et al. Inhibition of macrophage function prevents intestinal inflammation and postoperative ileus in rodents. Gut 2007;56:176-85.
13. Lee YG, Chain BM, Cho JY. Distinct role of spleen tyrosine kinase in the early phosphorylation of inhibitor of kappaB alpha via activation of the phosphoinositide-3-kinase and Akt pathways. Int J Biochem Cell Biol 2009;41:811-21.
14. Ulanova M, Asfaha S, Stenton G, et al. Involvement of Syk protein tyrosine kinase in LPS-induced responses in macrophages. J Endotoxin Res 2007;13:117-25. (Pubitemid 47471328)
15. Stenton GR, Ulanova M, Dery RE, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169: 1028-36. (Pubitemid 34753463)
16. Liddle J, Atkinson FL, Barker MD, et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg Med Chem Lett 2011;21:6188-94.
17. Marim FM, Silveira TN, Lima DS Jr, et al. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One 2010;5:e15263.
18. The F, Cailotto C, van d V, et al. Central activation of the cholinergic anti-inflammatory pathway reduces surgical inflammation in experimental post-operative ileus. Br J Pharmacol 2011;163:1007-16.
19. Schmidt J, Stoffels B, Moore BA, et al. Proinflammatory role of leukocyte-derived Egr-1 in the development of murine postoperative ileus. Gastroenterology 2008;135:926-36, 936.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
21. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008;112:935-45.
22. Costello PS, Turner M, Walters AE, et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 1996;13:2595-605. (Pubitemid 27046115)
23. Matsubara S, Li G, Takeda K, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006;173:56-63. (Pubitemid 43069788)
24. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387-402.
25. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5.
26. Denyer J, Patel V. Syk kinase inhibitors in allergic diseases. Drug News Perspect 2009;22:146-50.
27. Malbec O, Roget K, Schiffer C, et al. Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type mouse mast cells. J Immunol 2007;178:6465-75. (Pubitemid 46717430)
28. Bueno L, Fioramonti J, Delvaux M, et al. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997;112:1714-43. (Pubitemid 27181399)
29. van der Kleij HP, Ma D, Redegeld FA, et al. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol 2003;171:2074-9. (Pubitemid 36966491)
30. Bueb JL, Mousli M, Landry Y, et al. A pertussis toxin-sensitive G protein is required to induce histamine release from rat peritoneal mast cells by bradykinin. Agents Actions 1990;30:98-101. (Pubitemid 20142251)
31. Mousli M, Hugli TE, Landry Y, et al. Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 1994;27:1-11. (Pubitemid 24051065)
32. Mousli M, Bronner C, Landry Y, et al. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 1990;259:260-2. (Pubitemid 20025810)
33. Chahdi A, Mousli M, Landry Y. Substance P-related inhibitors of mast cell exocytosis act on G-proteins or on the cell surface. Eur J Pharmacol 1998;341:329-35. (Pubitemid 28131132)
34. Lorenz D, Wiesner B, Zipper J, et al. Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies. J Gen Physiol 1998;112:577-91. (Pubitemid 28518957)
35. Bueb JL, Mousli M, Bronner C, et al. Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells. Mol Pharmacol 1990;38:816-22.
36. Moon KD, Post CB, Durden DL, et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 2005;280:1543-51.
37. Mousli M, Bronner C, Bueb JL, et al. Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther 1989;250:329-35. (Pubitemid 19195009)
38. Kobayashi S, Somlyo AV, Somlyo AP. Heparin inhibits the inositol 1,4,5-trisphosphate-dependent, but not the independent, calcium release induced by guanine nucleotide in vascular smooth muscle. Biochem Biophys Res Commun 1988;153:625-31.
39. Ahmed T, Syriste T, Mendelssohn R, et al. Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation? J Appl Physiol 1994;76:893-901. (Pubitemid 24075641)
40. Patou J, Holtappels G, Affleck K, et al. Syk-kinase inhibition prevents mast cell activation in nasal polyps. Rhinology 2011;49:100-6.
41. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18.
42. de Jonge WJ, The FO, van der Coelen D, et al. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology 2004;127:535-45. (Pubitemid 39091902)
43. The FO, Bennink RJ, Ankum WM, et al. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut 2008;57:33-40.
44. Snoek SA, Dhawan S, van Bree SH, et al. Mast cells trigger epithelial barrier dysfunction, bacterial translocation and postoperative ileus in a mouse model. Neurogastroenterol Motil 2011;24:172-84.
45. Mecheri S, David B. Unravelling the mast cell dilemma: culprit or victim of its generosity? Immunol Today 1997;18:212-15. (Pubitemid 27219614)
46. Pamuk ON, Tsokos GC. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 2010;12:222.
47. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115:791-6. (Pubitemid 40460855)
48. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-60.
49. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
50. Rivera J, Colbert RA. Healing the Syk through kinase inhibitors. N Engl J Med 2010;363:1362-4.